IO-202 + azacitidine + venetoclax

IO-202 + azacitidine + venetoclax is a combination therapy under clinical investigation for the treatment of hematologic malignancies, particularly chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML). IO-202 is a first-in-class humanized IgG1 monoclonal antibody that targets leukocyte immunoglobulin-like receptor B4 (LILRB4), also known as ILT3. LILRB4 is predominantly expressed on monocytes and monocytic blasts in certain blood cancers. By binding to LILRB4 with high affinity and specificity, IO-202 induces antibody-dependent cellular cytotoxicity and phagocytosis of malignant cells[1][2][5][6]. Azacitidine is a hypomethylating agent that inhibits DNA methylation, leading to reactivation of tumor suppressor genes. Venetoclax is a small molecule inhibitor of BCL-2, promoting apoptosis in cancer cells. The combination aims to enhance anti-tumor immune responses by both direct cytotoxic effects on malignant cells and modulation of the tumor microenvironment. Clinical trials are ongoing to evaluate safety and efficacy in patients with newly diagnosed CMML who have not received prior hypomethylating agents[5][6][8].